Sharing my story helps raise awareness about pulmonary fibrosis

Tyvaso boosts lung function in IPF trial, per top-line data

The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The top-line result means that the Phase 3 TETON 2 clinical trial (NCT05255991) has met its main goal. Tyvaso’s developer, United…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums